Bioniche Life Sciences Inc. Enters into an Exclusive U.S. Distribution Agreement for an Equine Product
- MitoHorse(TM )is a probiotic capsule for horses -
BELLEVILLE, ON, Aug. 13, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based,
technology-driven Canadian biopharmaceutical company, today announced
that it has entered into a distribution agreement with Imagilin
Technology LLC, a U.S.-based veterinary pharmaceutical company to
distribute MitoHorse(TM), an equine probiotic.
Probiotics work by ensuring a proper balance of good bacteria in the
body to enable the absorption of food and nutrients so that the
intestines are not overrun with toxins and waste. With a balanced
intestinal system, the body is better able to fight illness and
inflammation and help prevent the onset of disease (Lin et al, 2009).
MitoHorse(TM) is a special formula of two beneficial microorganisms, Pediococcus acidilactici, and Saccharomyces boulardii. Both microorganisms are naturally found in animal and human intestines.
The formula is designed for the long GI tracts of horses and ponies.
When horses and ponies are under stress from environmental changes,
they often experience digestive disorders and have weakened immune
systems. Experimental studies have demonstrated that horses and ponies
fed with MitoHorse(TM) suffer from fewer stress-related digestive
discomforts (Wilson, DA, 2012).
“This product is a welcome addition to the U.S. product portfolio,
complementing our existing line of equine feed supplements and the
recently introduced Gastrafate®, a GI mucosal protectant that promotes
self-healing of equine gastric ulcer syndrome,” said Mr. Andrew Grant,
President of Bioniche Animal Health (global).
About Imagilin Technology LLC
Founded in 2003, Imagilin Technology, is a biotechnology company located
in Maryland, USA. The company specializes in innovative products and
technology to improve human and animal health and nutrition. Imagilin
Technology focuses on probiotics as an essential part of nutraceutical
products to support human and animal immune and digestive systems. The
company has successfully introduced MitoMax®, a patent-pending
probiotic product line for animals, to the pet industry and has
established close distribution partnerships in North and South America,
and Asia. MitoHorse(TM )is the equine formulation of this product line. The company has been
closely involved with basic research and clinical studies worldwide for
all of its products. The results of the research have been published in
several scientific magazines and journals.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company’s primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
Bioniche Animal Health develops, manufactures and markets veterinary
biopharmaceutical products worldwide. In North America, it has
development, manufacturing and marketing facilities in Belleville,
Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington,
U.S.A. In Australia, business is conducted from two sites: Sydney, New
South Wales, where sales and marketing, customer support and technical
service are located; and Armidale, New South Wales, where research,
development and manufacturing facilities are located.
Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small
and Medium-Sized Employers in Canada for 2011. For more information,
please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company’s current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company’s ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.